• Osteopore secures market approvals for orthopaedic products in Singapore and Vietnam
• Wins tender bids to supply products to two major public hospitals in Vietnam
• Products include Osteopore's centerpiece high tibial osteotomy (HTO) and bone grafting products

Osteopore Limited, an Australian-Singaporean regenerative medicine company, has announced that it has gained entry into two major public hospitals in Vietnam for its orthopaedic products. The products that were successful in the tender bids included Osteopore's centerpiece product for high tibial osteotomy (HTO), and other products for bone grafting applications. The tender value for both hospitals is approximately AUD 90,000 over the first 12 months. This comes after Osteopore secured Singapore and Vietnam market approvals for its orthopaedic products in March 2024. The HTO market is projected to grow at a CAGR of 9.2% with procedures expected to reach 35,000 in the Asia Pacific region (APAC) annually by 2025. Additionally, the bone grafting market is expected to increase at a CAGR of 2.3%, with procedures reaching 250,000 in APAC annually by 2025. Vietnam's orthopaedic market is forecasted to experience robust growth at a 7.68% CAGR between 2024 and 2028, driven by the country's aging population and the increasing prevalence of orthopaedic conditions. Osteopore is now working with its distribution partner in Vietnam to finalise logistics and supply arrangements with the two hospitals, which is expected to complete over the next 3 months.

Osteopore is working towards making further commercial progress for its orthopaedic products not just in Vietnam, but also in other markets that it has identified.